<DOC>
	<DOCNO>NCT02662855</DOCNO>
	<brief_summary>The purpose study explore therapeutic efficacy Favipiravir , broad-spectrum antiviral drug severe case Ebola Virus Disease ( EVD ) , difficult aspect clinical management EVD due high fatality rate .</brief_summary>
	<brief_title>Efficacy Favipiravir Against Severe Ebola Virus Disease</brief_title>
	<detailed_description>This prospective , open-label , control phase 2 trial Favipiravir among severe case ( case hemorrhage , severe dehydration , consciousness disorder , shock , high blood viral load Ct value 20 ) confirm EVD patient capital area Sierra Leone . Patients 13 year age old would assign 1:1 randomised manner receive WHO-recommended therapy ( mainly symptomatic supportive therapy , control group . WHO , World Health Organization . ) oral Favipiravir ( 1600 mg twice first day , follow twice-daily dose 600 mg negative blood viral load detection death ) plus WHO-recommended therapy ( treatment group ) . The primary efficacy end point case fatality rate.The secondary efficacy endpoint blood ( plasma ) viral load . Optimal inclusion number 240 case ( 120 group ) , consider actual situation pandemic area , front line doctor right reset inclusion number , modify study protocol accord actual situation front .</detailed_description>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Hemorrhagic Fever , Ebola</mesh_term>
	<criteria>Male famaleï¼Œ13 75 year age Clinical diagnosis EVD Positive blood viral RNA detection With one symptom : Hemorrhage ( include hematemesis , hemoptysis , hematochezia , hematuria , mucocutaneous hemorrhage ) , severe dehydration ( include oliguria , anuria , feebleness , hypotension , tachycardia ) , consciousness disorder ( include coma , delirium , confusion , convulsion ) , shock , high blood viral load ( Ct value 20 ) Not receive therapy EVD Provided write informed consent , guardian patient Be able administrate tolerate oral administration tablet Severe vomit Pregnancy breastfeed Received antiviral treatment EVD</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>